personnel · US Department of Defense · Rule · Published 2018-12-11 · Effective 2018-12-11 · 83 FR 63574
Document
Document number
2018-26562
Federal Register citation
83 FR 63574
CFR reference
32 CFR 199
Type
Rule
Action
Interim final rule.
Category
personnel
Sub-agency
US Department of Defense
Publication date
2018-12-11
Effective date
2018-12-11
DOD docket
DOD-2018-HA-0062
Abstract
This interim final rule implements Section 702 of the National Defense Authorization Act for Fiscal Year 2018 (NDAA FY18). The law makes significant changes to the TRICARE Pharmacy Benefits Program, specifically it: Updates co-payment requirements; authorizes a new process for encouraging use of pharmaceutical agents that provide the best clinical effectiveness by excluding coverage for particular pharmaceutical agents that provide very little or no clinical effectiveness relative to similar agents and for giving preferential status to agents that provide enhanced clinical effectiveness; and authorizes special reimbursement methods, amounts, and procedures to encourage use or high-value products and discourage use of low-value products with respect to pharmaceutical agents provided as part of medical services from authorized providers.